Cannabis ETFs and Investment Vehicles in 2026: Performance, Holdings, and Outlook

The cannabis investment landscape in 2026 looks almost nothing like it did during the speculative mania of 2018 or the crushing bear market of 2022-2023. The sector has matured, consolidated, and — most importantly — begun generating the kind of financial fundamentals that institutional investors actually care about. Cannabis ETFs, once the domain of retail speculators chasing moonshot returns, have evolved into legitimate investment vehicles with distinct strategies, meaningful differentiation, and track records long enough to evaluate.

Whether you are a long-term investor considering cannabis exposure or an industry participant trying to understand how capital markets view your sector, this guide breaks down the current state of cannabis ETFs and adjacent investment options.

The Current Cannabis ETF Landscape

The cannabis ETF market has consolidated significantly since the proliferation of funds in 2018-2019. Several early entrants closed or merged, and the surviving funds have carved out distinct niches. Here is where things stand in early 2026.

MSOS — AdvisorShares Pure US Cannabis ETF

AUM: ~$1.8 billion Expense Ratio: 0.83% YTD Return (2026): +14.2%

MSOS remains the dominant vehicle for US multi-state operator (MSO) exposure. The fund holds swap agreements that provide economic exposure to companies like Curaleaf, Green Thumb Industries, Trulieve, and Verano — companies that trade on US OTC markets because federal prohibition still prevents major exchange listings.

The swap structure is a workaround for the prohibition-era restriction that prevents US-listed ETFs from directly holding securities of companies that violate federal law. It adds complexity and cost, but it is currently the only game in town for passive US cannabis exposure.

MSOS has been the primary beneficiary of renewed federal reform optimism in 2026. Every time a rescheduling headline hits, this fund moves. The volatility is a feature for traders and a risk for long-term holders, but the underlying companies are genuinely improving their financial profiles. Many of the top holdings are now generating positive free cash flow even under the punitive 280E tax regime — a topic our article on cannabis industry accounting challenges examines in depth.

MJ — ETFMG Alternative Harvest ETF

AUM: ~$520 million Expense Ratio: 0.75% YTD Return (2026): +8.7%

MJ takes a broader approach, holding a mix of Canadian licensed producers, US-adjacent companies, and international cannabis firms. Its top holdings include Tilray, Canopy Growth, and various ancillary companies that provide services to the cannabis industry without touching the plant directly.

The fund’s diversified approach has been both its strength and weakness. It avoided the worst of the US MSO drawdowns but also missed the strongest rebounds. For investors who want cannabis exposure without concentrated US regulatory risk, MJ offers a middle path.

YOLO — AdvisorShares Pure Cannabis ETF

AUM: ~$280 million Expense Ratio: 0.76% YTD Return (2026): +11.5%

YOLO blends US and Canadian cannabis companies in a single actively managed portfolio. The fund’s management team has been shifting allocation toward US operators as the regulatory environment improves, making it increasingly correlated with MSOS but with Canadian diversification.

THCX — Cannabis ETF (Roundhill)

AUM: ~$150 million Expense Ratio: 0.59% YTD Return (2026): +9.1%

The lowest-cost option in the cannabis ETF space, THCX tracks an index of global cannabis companies weighted by market capitalization. Its passive approach and lower fees make it appealing for cost-conscious investors, though its index methodology means it holds some companies with tenuous connections to the cannabis industry.

Performance Context: The Five-Year View

Understanding cannabis ETF performance requires context that goes beyond YTD numbers. Here is the trajectory:

2021: Most cannabis ETFs peaked in February 2021 on federal legalization optimism following Democratic control of Congress. MSOS hit an all-time high of approximately $55 per share.

2022-2023: A brutal bear market as federal reform stalled, state-level oversupply crushed margins, and rising interest rates punished growth stocks broadly. MSOS fell below $7 — a decline exceeding 85% from its peak.

2024: Stabilization and early recovery. The DEA rescheduling process generated headline momentum, and several large MSOs reported their first sustained periods of positive cash flow.

2025: A year of genuine progress. Rescheduling moved forward, 280E relief appeared increasingly likely, and several state markets matured into profitability. MSOS returned approximately 40% for the year.

2026 YTD: Continued momentum driven by state market expansion and federal policy progress, though the pace of gains has moderated as much of the good news is now priced in.

For investors who entered during the 2022-2023 lows, returns have been exceptional. For those who bought the 2021 peaks, the recovery still has a long way to go.

What Is Actually Driving Cannabis Stock Performance?

Cannabis equities in 2026 are being driven by a fundamentally different set of catalysts than in previous cycles:

280E Reform

Section 280E of the Internal Revenue Code prevents cannabis companies from deducting ordinary business expenses, resulting in effective tax rates of 60-80% for many operators. Rescheduling cannabis from Schedule I to Schedule III would eliminate this burden, instantly improving operating margins by 20-30 percentage points for most MSOs. This single policy change represents the largest near-term value catalyst in the sector. The complexity of operating under 280E is something every cannabis business contends with — our detailed analysis of cannabis accounting challenges explains the mechanics.

State Market Maturation

The most important but least discussed driver is the maturation of state-level markets. States like Illinois, New Jersey, and Missouri that launched adult-use sales in 2022-2024 are now reaching stable-state revenue levels. Operators in these markets have moved past the initial capital-intensive buildout phase and are generating meaningful cash flow.

Consolidation

The cannabis industry’s long-awaited consolidation wave is finally underway. Distressed operators are being acquired at discounts, and well-capitalized MSOs are expanding their footprints without the dilutive capital raises that characterized previous expansion cycles.

International Expansion

Germany’s cannabis market continues to develop, and several other European countries are advancing legalization frameworks. While international revenue remains a small fraction of total cannabis industry sales, it represents a long-term growth runway that investors are beginning to price in.

Beyond ETFs: Alternative Cannabis Investment Vehicles

ETFs are not the only way to invest in cannabis. Several alternative vehicles deserve consideration:

Cannabis REITs

Innovative Industrial Properties (IIPR) remains the dominant cannabis-focused REIT, owning cultivation and processing facilities leased to cannabis operators. The company offers dividend income — a rarity in the cannabis sector — and provides real estate exposure with cannabis growth characteristics. However, IIPR’s tenant concentration risk became apparent during the 2022-2023 downturn when several tenants struggled to make rent.

Private Funds

Several private equity and venture funds focus on cannabis, offering access to pre-IPO companies and private operators. These vehicles require accredited investor status and longer lock-up periods but can provide exposure to parts of the industry not available through public markets.

Ancillary Companies

Companies that serve the cannabis industry without touching the plant — lighting manufacturers, hydroponics suppliers, packaging companies, compliance software providers — trade on major exchanges without the regulatory complications of plant-touching businesses. Our guide to LED grow light comparisons touches on the technology companies that benefit from cannabis cultivation expansion.

Direct Stock Purchases

For investors comfortable with individual stock selection, directly purchasing shares of specific MSOs or Canadian LPs offers higher potential returns (and higher risk) than diversified ETF exposure. This approach requires more research but avoids ETF expense ratios and allows precise portfolio construction.

Risk Factors to Watch

Cannabis investing carries sector-specific risks that standard equity analysis may not capture:

Federal Policy Reversal: While the trend toward federal reform appears durable, a change in administration or congressional makeup could slow or reverse progress.

State-Level Oversupply: Several mature state markets are experiencing supply gluts that compress wholesale prices and operator margins. This is a structural challenge that consolidation will eventually address but that can cause significant near-term pain.

Banking and Exchange Listing: Until cannabis companies can access normal banking services and list on major exchanges, the sector will trade at a structural discount to comparable consumer goods companies.

Illicit Market Competition: Despite years of legalization, the illicit cannabis market remains larger than the legal market nationally. Price parity between legal and illicit products is the key variable — and it has not been achieved in most states.

The Investment Thesis in 2026

The bull case for cannabis investment in 2026 is straightforward: you are buying into an industry that generates approximately $30 billion in annual US revenue, is growing in the mid-single digits organically, and is on the verge of regulatory changes that will dramatically improve operator economics. The leading MSOs trade at 5-8x EBITDA — a significant discount to comparable consumer staples companies that trade at 12-18x.

The bear case is equally straightforward: federal reform has been “just around the corner” for years, the illicit market remains a formidable competitor, and many cannabis companies carry significant debt loads accumulated during the growth-at-all-costs era.

For most investors, a small allocation to cannabis through one of the major ETFs — sized appropriately for a speculative but improving sector — represents the most sensible approach. The industry’s fundamentals have never been stronger, but the regulatory uncertainty means position sizing matters more than stock selection.

The days of cannabis as a meme-stock trade are over. What is emerging in its place is a real industry with real businesses generating real cash flow. The ETFs tracking this sector reflect that maturation — and for patient investors, the risk-reward profile in 2026 is as favorable as it has been since legalization began.